Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Pfizer Seeks Methotrexate Label Expansion for GVHD Prevention
Pfizer said on March 26 that it has filed a public knowledge-based application in Japan, seeking to widen the label of its folate antimetabolite methotrexate for the prevention of graft-versus-host disease (GVHD) associated with hematopoietic stem cell transplantation. The submission…
To read the full story
Related Article
BUSINESS
- Takeda to Nominate CEO-Elect Kim to Board at June AGM
March 27, 2026
- Meiji Pharma, KM Biologics Begin PIII for 6-in-1 Vaccine
March 27, 2026
- J-TEC Files Dried Allogeneic Cultured Epidermis in Japan
March 27, 2026
- Pfizer Seeks Methotrexate Label Expansion for GVHD Prevention
March 27, 2026
- Ono Files Japan NDA For Deciphera-Originated GIST Drug Qinlock
March 27, 2026
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…